Takara Bio starts phase I for therapy of pancreatic cancer using oncolytic virus (HF 10) in combination with chemotherapy

The test (TBI-1401) on patients with uncurable and unresectable pancreatic cancer is targeted to evaluate dose-limiting toxicity. HF 10 is administered intratumorally by ultrasonic endoscope., and gemcitabine and nab paclitaxel are administered in combination.

Takara Bio news release, June 1, 2017

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny